AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25516158 — intervention group
Group type: EXPERIMENTAL
Intervention: ActWell programme
Number of subjects: 65
Study 25516158 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 65
Study 21947182 — intervention group
Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled prosthetic knee joints
Number of subjects: 41
Study 21947182 — intervention group
Group type: COMPARATOR
Intervention: Mechanically controlled knee joint
Number of subjects: 41
Study 19703938 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation debriefing
Number of subjects: 74
Study 19703938 — intervention group
Group type: COMPARATOR
Intervention: Home study
Number of subjects: 74
Study 19703938 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 74
Study 19703938 — intervention group
Group type: COMPARATOR
Intervention: Both groups (debriefed and control)
Number of subjects: 74
Study 16723306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) with different estrogen/progestogen profiles: EE 20 microg/desogestrel 150 microg, EE 30 microg/desogestrel 150 microg, EE 30 microg/gestodene 75 microg
Number of subjects: 113
Study 16723306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine devices (IUDs)
Number of subjects: 113
Study 16723306 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 age-matched diabetic women not using contraception)
Number of subjects: 113
Study 15261219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet release before wound closure (Group A)
Number of subjects: 80
Study 15261219 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet release after skin closure (Group B)
Number of subjects: 80
Study 15261219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented group (Group A+)
Number of subjects: 80
Study 15261219 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cemented group (Group A-)
Number of subjects: 80
Study 15261219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented group (Group B+)
Number of subjects: 80
Study 15261219 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cemented group (Group B-)
Number of subjects: 80
Study 11513286 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based teaching approach with structured rating guidelines
Number of subjects: 34
Study 11513286 — intervention group
Group type: COMPARATOR
Intervention: Control group (not prepared with case-based approach)
Number of subjects: 34
Study 9505453 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 2992
Study 9505453 — intervention group
Group type: COMPARATOR
Intervention: Reporting a genital ulcer during follow up
Number of subjects: 2992
Study 9505453 — intervention group
Group type: COMPARATOR
Intervention: Having multiple sexual partners
Number of subjects: 2992
Study 9505453 — intervention group
Group type: COMPARATOR
Intervention: Having a urethral discharge
Number of subjects: 2992
Study 9505453 — intervention group
Group type: COMPARATOR
Intervention: Being single
Number of subjects: 2992
Study 9505453 — intervention group
Group type: COMPARATOR
Intervention: Widowed or married but not residing with wife
Number of subjects: 2992
Study 8173698 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1208
Study 8173698 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1208
Study 8173698 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 1208
Study 3524923 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid and chlorambucil for six months
Number of subjects: 25
Study 1091124 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate
Number of subjects: 0
Study 1091124 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 0
Study 31035080 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect condition
Number of subjects: 174
Study 31035080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette cue condition
Number of subjects: 174
Study 31035080 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 174
Study 31035080 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall momentary quit motivation
Number of subjects: 174
Study 28544202 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated arm ergometry every 30 minutes
Number of subjects: 13
Study 28544202 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting only
Number of subjects: 13
Study 27101669 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) and standardized treatment (glucocorticoid nasal spray)
Number of subjects: 36
Study 27101669 — intervention group
Group type: COMPARATOR
Intervention: Standardized treatment (glucocorticoid nasal spray)
Number of subjects: 36
Study 23815304 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational computer-based treatment
Number of subjects: 25
Study 21775530 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein, high dairy (HPHD)
Number of subjects: 90
Study 21775530 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate protein, medium dairy (APMD)
Number of subjects: 90
Study 21775530 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate protein, low dairy (APLD)
Number of subjects: 90
Study 21775530 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 90
Study 19480669 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 72
Study 19480669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 18043146 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed PRBC (P group, n = 8)
Number of subjects: 16
Study 14680996 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper respiratory tract illnesses (URTIs)
Number of subjects: 48
Study 14680996 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study 11731751 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30
Study 11731751 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study 9230790 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemether (500 mg over five days)
Number of subjects: 151
Study 9230790 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemether (750 mg over seven days)
Number of subjects: 151
Study 9230790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment of oral artemether (600 mg) followed by mefloquine (1,250 mg)
Number of subjects: 151
Study 9230790 — intervention group
Group type: COMPARATOR
Intervention: All groups (I, II, III)
Number of subjects: 151
Study 8219859 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine treatment
Number of subjects: 32
Study 8219859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3319349 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg b.i.d.)
Number of subjects: 10
Study 3319349 — intervention group
Group type: COMPARATOR
Intervention: Sulindac (200 mg b.i.d.)
Number of subjects: 10
Study 29234943 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 119
Study 29234943 — intervention group
Group type: COMPARATOR
Intervention: Traditional Care
Number of subjects: 119
Study 27599227 — intervention group
Group type: EXPERIMENTAL
Intervention: Marriage Checkup adapted for independent practice (MC‐P)
Number of subjects: 233
Study 27599227 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition (WL)
Number of subjects: 233
Study 25301881 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard automated perimetry (SAP) in OSA patients
Number of subjects: 80
Study 25301881 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy individuals)
Number of subjects: 80
Study 23423595 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression gloves
Number of subjects: 57
Study 23423595 — intervention group
Group type: COMPARATOR
Intervention: Control group without compression treatment
Number of subjects: 57
Study 20722471 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (60 minutes, 3 times a week for 12 weeks)
Number of subjects: 34
Study 20722471 — intervention group
Group type: COMPARATOR
Intervention: Walking intervention (60 minutes, 3 times a week for 12 weeks)
Number of subjects: 34
Study 20722471 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 34
Study 19140648 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time strategy video game training for 23.5 hours
Number of subjects: 0
Study 19140648 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16819378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral family intervention with standard pediatric care
Number of subjects: 32
Study 16819378 — intervention group
Group type: COMPARATOR
Intervention: Standard pediatric care
Number of subjects: 32
Study 15504185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketobemidone (1 mg ml(‐1))
Number of subjects: 60
Study 15504185 — intervention group
Group type: COMPARATOR
Intervention: Morphine (1 mg ml(‐1))
Number of subjects: 60
Study 15504185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketobemidone
Number of subjects: 60
Study 15504185 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 60
Study 11128732 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert physiotherapists measuring post-stroke shoulder pain using 100 mm vertical visual analogue scales (VAS) for intensity, frequency, and affective response.
Number of subjects: 33
Study 11128732 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert physiotherapists measuring site-of-pain using a categorical site-of-pain scale.
Number of subjects: 33
Study 9139098 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial placement of the patellar component on the medial two thirds of the patellar bone.
Number of subjects: 62
Study 9139098 — intervention group
Group type: COMPARATOR
Intervention: Centrally placed patellar component.
Number of subjects: 62
Study 8362431 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 125
Study 8362431 — intervention group
Group type: COMPARATOR
Intervention: Control (no warfarin)
Number of subjects: 125
Study 8362431 — intervention group
Group type: COMPARATOR
Intervention: Control (aspirin therapy)
Number of subjects: 125
Study 8362431 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin therapy)
Number of subjects: 125
Study 2869952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg to 60 mg once daily)
Number of subjects: 40
Study 2869952 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol (200 mg to 600 mg once daily)
Number of subjects: 40
Study 30532522 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based health promotion program with a person-centered approach (4 weeks of group intervention and one follow-up home visit)
Number of subjects: 131
Study 30532522 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based health promotion program with a person-centered approach
Number of subjects: 131
Study 30532522 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention but access to ordinary health care services)
Number of subjects: 131
Study 27454540 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Interlaminar Discectomy (PEID)
Number of subjects: 60
Study 27454540 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Endoscopic Transforaminal Discectomy (PETD)
Number of subjects: 60
Study 24657310 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based exposure/response prevention therapy (E/RP)
Number of subjects: 31
Study 24657310 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 31
Study 22565936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker ON (dual-chamber pacing with rate drop response)
Number of subjects: 89
Study 22565936 — intervention group
Group type: COMPARATOR
Intervention: Pacemaker OFF (sensing only)
Number of subjects: 89
Study 21104944 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream 0.05% (Finalgon® CPDWärmecreme)
Number of subjects: 281
Study 21104944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 18182416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (2 mg)
Number of subjects: 96
Study 18182416 — intervention group
Group type: COMPARATOR
Intervention: Dihydrocodeine (240 mg)
Number of subjects: 96
Study 16095893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized sodium cromoglycate (3-4 times/day)
Number of subjects: 251
Study 16095893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized sodium cromoglycate (3-4 times/day) in atopic patients
Number of subjects: 251
Study 16095893 — intervention group
Group type: COMPARATOR
Intervention: Control group (Isotonic saline)
Number of subjects: 251
Study 12969694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen alone or with alendronate
Number of subjects: 173
Study 12969694 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen alone or with alendronate
Number of subjects: 173
Study 12969694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy alone
Number of subjects: 173
Study 12969694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy plus alendronate
Number of subjects: 173
Study 10655861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocellular dressing
Number of subjects: 40
Study 10655861 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 40
Study 8542129 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP
Number of subjects: 17
Study 8542129 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 1905509 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/hMG/hCG
Number of subjects: 7
Study 1905509 — intervention group
Group type: COMPARATOR
Intervention: hMG/hCG
Number of subjects: 7
Study 1905509 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/hMG
Number of subjects: 7
Study 6221247 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 1 mg/kg/24 h for one month, then decreasing dosage; cyclophosphamide 2 mg/kg/24 h if failure at one month
Number of subjects: 14
Study 6221247 — intervention group
Group type: COMPARATOR
Intervention: Prednisone with 3 plasma exchanges over a 10-day period, continued weekly if required
Number of subjects: 14
Study 6221247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 30644108 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Depression Awareness Program (ADAP)
Number of subjects: 1427
Study 30644108 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1427
Study 29952046 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived relationship to health care provider
Number of subjects: 187
Study 27071963 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (zona thinning)
Number of subjects: 178
Study 27071963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser-assisted hatching)
Number of subjects: 178
Study 24518158 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐cell depleting induction therapy
Number of subjects: 306
Study 21383687 — intervention group
Group type: EXPERIMENTAL
Intervention: cGVHD
Number of subjects: 12
Study 21383687 — intervention group
Group type: COMPARATOR
Intervention: SS
Number of subjects: 12
Study 21383687 — intervention group
Group type: COMPARATOR
Intervention: MGD
Number of subjects: 12
Study 20394851 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous, hyperfractionated, accelerated radiotherapy (CHART)
Number of subjects: 918
Study 20394851 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 918
Study 17397735 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary posterior continuous curvilinear capsulorhexis (PCCC)
Number of subjects: 52
Study 17397735 — intervention group
Group type: COMPARATOR
Intervention: No primary posterior continuous curvilinear capsulorhexis (non-PCCC)
Number of subjects: 52
Study 16277026 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 2
Study 16277026 — intervention group
Group type: COMPARATOR
Intervention: Single oestrogen
Number of subjects: 2
Study 12144587 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (1-4 mg b.d.)
Number of subjects: 52
Study 12144587 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 52
Study 12144587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 10574305 — intervention group
Group type: EXPERIMENTAL
Intervention: Milkshake preload
Number of subjects: 58
Study 10574305 — intervention group
Group type: COMPARATOR
Intervention: No preload
Number of subjects: 58
Study 8653184 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure method of service delivery
Number of subjects: 0
Study 8653184 — intervention group
Group type: COMPARATOR
Intervention: Non-disclosure method of service delivery
Number of subjects: 0
Study 8653184 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-test result values with prompts
Number of subjects: 0
Study 8653184 — intervention group
Group type: COMPARATOR
Intervention: Pre-test result values without prompts
Number of subjects: 0
Study 2354600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing water enema followed by DCBE at 15 minutes
Number of subjects: 59
Study 2354600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing water enema followed by DCBE at 30 minutes
Number of subjects: 59
Study 2354600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing water enema followed by DCBE at 45 minutes
Number of subjects: 59
Study 2354600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing water enema followed by DCBE at 60 minutes
Number of subjects: 59
Study 7378008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% naphazoline hydrochloride
Number of subjects: 6
Study 7378008 — intervention group
Group type: COMPARATOR
Intervention: Other nonprescription decongestant preparations
Number of subjects: 6
Study 7378008 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of naphazoline
Number of subjects: 6
Study 31600032 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile Arthritis (JA)
Number of subjects: 232
Study 27816940 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment (mean daily dose: 18.1 mg)
Number of subjects: 203
Study 27816940 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic observation (nonmedicated group)
Number of subjects: 203
Study 26606435 — intervention group
Group type: EXPERIMENTAL
Intervention: HYC‐24L (24 mg/mL of hyaluronic acid, 0.3% lidocaine)
Number of subjects: 136
Study 26606435 — intervention group
Group type: COMPARATOR
Intervention: CPM‐22.5 (22.5 mg/mL of hyaluronic acid)
Number of subjects: 136
Study 24338168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine (250 mg/m(2)) 6-h infusion on days 1 and 8, and cisplatin (70 mg/m(2)) on day 2 every 21-day cycle (arm 1)
Number of subjects: 120
Study 24338168 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose gemcitabine (1,250 mg/m(2)) 30-min infusion on days 1 and 8, with the same dose of cisplatin (arm 2)
Number of subjects: 120
Study 22717496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal Function Exercise (VFE) program
Number of subjects: 22
Study 22717496 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 19204651 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) paroxetine
Number of subjects: 18
Study 19204651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17458644 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg IV (group O)
Number of subjects: 108
Study 17458644 — intervention group
Group type: EXPERIMENTAL
Intervention: lornoxicam 8 mg IV (group L)
Number of subjects: 108
Study 17458644 — intervention group
Group type: COMPARATOR
Intervention: normal saline 2 ml IV (group P)
Number of subjects: 108
Study 15700725 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg plus zolpidem 0 mg
Number of subjects: 80
Study 15700725 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg plus melatonin 0 mg
Number of subjects: 80
Study 15700725 — intervention group
Group type: COMPARATOR
Intervention: Melatonin 0 mg plus zolpidem 0 mg
Number of subjects: 80
Study 15700725 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg alone
Number of subjects: 80
Study 11993610 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 1153
Study 11993610 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 1153
Study 11993610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1153
Study 9535248 — intervention group
Group type: EXPERIMENTAL
Intervention: PncD vaccine (1, 3, or 10 microg)
Number of subjects: 75
Study 9535248 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide vaccine
Number of subjects: 75
Study 9535248 — intervention group
Group type: EXPERIMENTAL
Intervention: PncD vaccine
Number of subjects: 75
Study 9535248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiologic saline)
Number of subjects: 75
Study 7733474 — intervention group
Group type: EXPERIMENTAL
Intervention: yrIL‐2 (1,000,000 U per 0.1 m2 body surface)
Number of subjects: 17
Study 7733474 — intervention group
Group type: EXPERIMENTAL
Intervention: yrIL‐2 added to therapeutic complex
Number of subjects: 17
Study 2645503 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg nandrolone decanoate (ND) intramuscularly every 3 weeks for 1 year
Number of subjects: 39
Study 2645503 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections every 3 weeks for 1 year
Number of subjects: 39
Study 31197540 — intervention group
Group type: EXPERIMENTAL
Intervention: P-COCC
Number of subjects: 98
Study 31197540 — intervention group
Group type: COMPARATOR
Intervention: Video
Number of subjects: 98
Study 31197540 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 98
Study 30351995 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-incision (2.25 mm)
Number of subjects: 67